Arcus Biosciences (RCUS) Tops Q4 EPS by 20c

Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($1.03), $0.20 better than the analyst estimate of ($1.23). Revenue for the quarter came in at $36 million versus the consensus estimate of $29.33 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
• JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral